Valuation: Cellink AB

Market Cap 144.68Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 56Cr 720.32Cr 56Cr 54Cr 2.29TCr P/E 2026 *
-6.37x
P/E 2027 * -11.5x
Enterprise Value 137.78Cr 14Cr 12Cr 12Cr 10Cr 20Cr 1.35TCr 20Cr 53Cr 685.97Cr 53Cr 52Cr 2.18TCr EV / Sales 2026 *
0.85x
EV / Sales 2027 * 0.76x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 51 01/09/2026
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 70 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member - 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 15Cr
+0.62%-0.03%+27.98%+19.00% 23TCr
+1.55%-2.12%+6.95%-19.82% 14TCr
+2.38%+3.07%-15.95%+24.43% 13TCr
+4.82%-5.75%-56.14%-14.87% 6.53TCr
+1.99%+0.96%-18.12%-13.93% 5.01TCr
+1.36%-4.87%+10.25%+15.54% 4.93TCr
-0.09%-2.69%+19.12%+27.79% 4.14TCr
+0.41%+0.15%+38.80%+50.73% 4.03TCr
+2.16%-2.35%-17.45%+51.04% 3.19TCr
Average +1.52%-2.00%-0.51%+15.54% 8.68TCr
Weighted average by Cap. +1.59%-1.32%+3.76%+11.08%

Financials

2026 *2027 *
Net sales 162.2Cr 17Cr 14Cr 14Cr 12Cr 23Cr 1.59TCr 23Cr 63Cr 807.55Cr 62Cr 61Cr 2.57TCr 168.55Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.65TCr 24Cr 65Cr 839.17Cr 65Cr 63Cr 2.67TCr
Net income -23Cr -2.32Cr -2.01Cr -1.9Cr -1.72Cr -3.23Cr -222.78Cr -3.26Cr -8.75Cr -113.02Cr -8.73Cr -8.54Cr -359.3Cr -13Cr -1.29Cr -1.12Cr -1.06Cr -95.71L -1.8Cr -123.66Cr -1.81Cr -4.86Cr -63Cr -4.85Cr -4.74Cr -199.44Cr
Net Debt -6.9Cr -70.65L -61.22L -57.77L -52.41L -98.32L -68Cr -99.04L -2.66Cr -34Cr -2.65Cr -2.6Cr -109.22Cr -17Cr -1.7Cr -1.47Cr -1.39Cr -1.26Cr -2.37Cr -162.92Cr -2.38Cr -6.4Cr -83Cr -6.38Cr -6.24Cr -262.75Cr
Logo Cellink AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!